lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer
| Autor: | Ming Xie, Yan He, Yijing Cao, Jing Wu, Tiebing Zeng, Yichen Luo, Wei Li, Hui Ling, Yuru Lu, Yu Zhou, Shan Xu |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cancer Research
Epithelial-Mesenchymal Transition Angiogenesis Inflammation Drug resistance Stomach Neoplasms Cell Line Tumor medicine Humans Epithelial–mesenchymal transition Pharmacology Cisplatin business.industry digestive oral and skin physiology Cancer Cell cycle Prognosis medicine.disease Long non-coding RNA Gene Expression Regulation Neoplastic Cancer research Molecular Medicine RNA Long Noncoding medicine.symptom business medicine.drug |
| Zdroj: | Anti-Cancer Agents in Medicinal Chemistry. 22:1440-1457 |
| ISSN: | 1871-5206 |
| Popis: | Gastric cancer is a global cancer with a high mortality rate. A growing number of studies have found the abnormal expression of lncRNA (long noncoding RNA) in many tumors, which plays a role in promoting or inhibiting cancer. Similarly, lncRNA abnormal expression plays an essential biological function in gastric cancer. This article focuses on lncRNA involvement in the development of gastric cancer in terms of cell cycle disorder, apoptosis inhibition, metabolic remodeling, promotion of tumor inflammation, immune escape, induction of angiogenesis, and Epithelial Mesenchymal Transition (EMT). The involvement of lncRNA in the development of gastric cancer is related to drug resistance, such as cisplatin and multi-drug resistance. It can also be used as a potential marker for the diagnosis and prognosis of gastric cancer and a target for the treatment. With an in-depth understanding of the mechanism of lncRNA in gastric cancer, new ideas for personalized treatment of gastric cancer are expected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|